Times to Discontinue Antidepressants Over 6 Months in Patients with Major Depressive Disorder
- PMID: 27482246
- PMCID: PMC4965655
- DOI: 10.4306/pi.2016.13.4.440
Times to Discontinue Antidepressants Over 6 Months in Patients with Major Depressive Disorder
Abstract
Objective: The aim of the present study was to investigate differences in discontinuation time among antidepressants and total antidepressant discontinuation rate of patients with depression over a 6 month period in a naturalistic treatment setting.
Methods: We reviewed the medical records of 900 patients with major depressive disorder who were initially prescribed only one kind of antidepressant. The prescribed antidepressants and the reasons for discontinuation were surveyed at baseline and every 4 weeks during the 24 week study. We investigated the discontinuation rate and the mean time to discontinuation among six antidepressants groups.
Results: Mean and median overall discontinuation times were 13.8 and 12 weeks, respectively. Sertraline and escitalopram had longer discontinuation times than that of fluoxetine, and patients who used sertraline discontinued use significantly later than those taking mirtazapine. No differences in discontinuation rate were observed after 24 weeks among these antidepressants. About 73% of patients discontinued antidepressant treatment after 24 weeks.
Conclusion: Sertraline and escitalopram tended to have longer mean times to discontinuation, although no difference in discontinuation rate was detected between antidepressants after 24 weeks. About three-quarters of patients discontinued antidepressant maintenance therapy after 24 weeks.
Keywords: Antidepressant; Discontinuation; Escitalopram; Major depressive disorder; Sertraline.
Similar articles
-
The comparative effectiveness of antidepressants for youths with major depressive disorder: a nationwide population-based study in Taiwan.Ther Adv Chronic Dis. 2022 May 22;13:20406223221098114. doi: 10.1177/20406223221098114. eCollection 2022. Ther Adv Chronic Dis. 2022. PMID: 35634571 Free PMC article.
-
Novel Augmentation Strategies in Major Depression.Dan Med J. 2017 Apr;64(4):B5338. Dan Med J. 2017. PMID: 28385173 Review.
-
Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial.BMJ. 2012 Mar 9;344:e1566. doi: 10.1136/bmj.e1566. BMJ. 2012. PMID: 22408266 Clinical Trial.
-
Impact of Sertraline, Fluoxetine, and Escitalopram on Psychological Distress among United States Adult Outpatients with a Major Depressive Disorder.Healthcare (Basel). 2023 Mar 3;11(5):740. doi: 10.3390/healthcare11050740. Healthcare (Basel). 2023. PMID: 36900745 Free PMC article.
-
A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network.Bipolar Disord. 2003 Dec;5(6):396-406. doi: 10.1046/j.1399-5618.2003.00065.x. Bipolar Disord. 2003. PMID: 14636363 Review.
Cited by
-
Real-world effects of antidepressants for depressive disorder in primary care: population-based cohort study.Br J Psychiatry. 2024 Dec 5;226(5):1-10. doi: 10.1192/bjp.2024.194. Online ahead of print. Br J Psychiatry. 2024. PMID: 39632598 Free PMC article.
-
Program of algorithm for pharmacological treatment of major depressive disorder in China: Benefits or not?Heliyon. 2023 Oct 17;9(11):e20951. doi: 10.1016/j.heliyon.2023.e20951. eCollection 2023 Nov. Heliyon. 2023. PMID: 37920522 Free PMC article.
-
Consequences of Recurrence of Major Depressive Disorder: Is Stopping Effective Antidepressant Medications Ever Safe?Focus (Am Psychiatr Publ). 2020 Apr;18(2):120-128. doi: 10.1176/appi.focus.20200008. Epub 2020 Apr 23. Focus (Am Psychiatr Publ). 2020. PMID: 33162849 Free PMC article.
-
Integrating Patients' Expectations into the Management of Their Depression: Report of a Symposium at the European College of Neuropsychopharmacology Congress.Adv Ther. 2019 Oct;36(Suppl 3):73-90. doi: 10.1007/s12325-019-01038-w. Epub 2019 Aug 9. Adv Ther. 2019. PMID: 31399884 Free PMC article.
-
The Dropout Rates and Associated Factors in Patients with Mood Disorders in Long-term Naturalistic Treatment.Clin Psychopharmacol Neurosci. 2024 May 31;22(2):263-275. doi: 10.9758/cpn.23.1089. Epub 2023 Jul 27. Clin Psychopharmacol Neurosci. 2024. PMID: 38627073 Free PMC article.
References
-
- Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593–602. - PubMed
-
- Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) JAMA. 2003;289:3095–3105. - PubMed
-
- Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA. 1989;262:914–919. - PubMed
-
- Murray CJ, Lopez AD. Evidence-based health policy--lessons from the Global Burden of Disease Study. Science. 1996;274:740–743. - PubMed
-
- Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry. 1993;54:405–418. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources